IV Levodopa ( DrugBank: Levodopa )
1 disease
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 6 | Parkinson disease | 5 |
6. Parkinson disease
Clinical trials : 2,307 / Drugs : 2,007 - (DrugBank : 349) / Drug target genes : 188 - Drug target pathways : 199
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT00108667 (ClinicalTrials.gov) | April 2005 | 15/4/2005 | Talampanel to Treat Parkinson's Disease | AMPA Receptor Antagonist Treatment of Parkinson's Disease | Parkinson Disease | Drug: IV Levodopa;Drug: Talampanel | National Institute of Neurological Disorders and Stroke (NINDS) | NULL | Completed | N/A | N/A | Both | 40 | Phase 2 | United States |
| 2 | NCT00040209 (ClinicalTrials.gov) | June 2002 | 21/6/2002 | JP-1730 to Treat Parkinson's Disease | Alpha-2 Adrenergic Antagonist Treatment of Parkinson's Disease | Parkinson Disease | Drug: JP 1730;Drug: IV Levodopa;Drug: IV Apomorphine | National Institute of Neurological Disorders and Stroke (NINDS) | NULL | Completed | N/A | N/A | Both | 30 | Phase 2 | United States |
| 3 | NCT00013624 (ClinicalTrials.gov) | March 2001 | 24/3/2001 | Riluzole to Treat Parkinson's Disease | Effect of Antiglutamatergic Treatment in Parkinson's Disease | Parkinson's Disease | Drug: IV Levodopa | National Institute of Neurological Disorders and Stroke (NINDS) | NULL | Completed | N/A | N/A | Both | 20 | Phase 2 | United States |
| 4 | NCT00009048 (ClinicalTrials.gov) | January 2001 | 23/1/2001 | EMD 128130 for the Treatment of Parkinson's Disease | Effect of Serotoninergic Treatment in Parkinson's Disease | Parkinson's Disease | Drug: EMD 128130;Drug: IV Levodopa | National Institute of Neurological Disorders and Stroke (NINDS) | NULL | Completed | N/A | N/A | Both | 30 | Phase 2 | United States |
| 5 | NCT00006337 (ClinicalTrials.gov) | October 2000 | 4/10/2000 | KW-6002 to Treat Parkinson's Disease | Adenosine A2A Blockade With KW-6002 in Parkinson's Disease | Parkinson's Disease | Drug: KW-6002;Drug: IV Levodopa | National Institute of Neurological Disorders and Stroke (NINDS) | NULL | Completed | N/A | N/A | Both | 16 | Phase 2 | United States |